Delaney Dennis R Acquires 633 Shares of Eli Lilly and Company $LLY

Delaney Dennis R lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 28.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,849 shares of the company’s stock after acquiring an additional 633 shares during the quarter. Eli Lilly and Company makes up 1.5% of Delaney Dennis R’s portfolio, making the stock its 26th biggest position. Delaney Dennis R’s holdings in Eli Lilly and Company were worth $3,062,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. Norges Bank bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $12,976,634,000. Capital Research Global Investors raised its holdings in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after acquiring an additional 4,332,008 shares in the last quarter. Cardano Risk Management B.V. raised its holdings in shares of Eli Lilly and Company by 876.1% during the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock valued at $2,552,419,000 after acquiring an additional 2,131,734 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares in the last quarter. Finally, Amundi raised its holdings in shares of Eli Lilly and Company by 27.1% during the third quarter. Amundi now owns 4,525,902 shares of the company’s stock valued at $3,823,977,000 after acquiring an additional 964,675 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY opened at $1,122.47 on Wednesday. The stock has a fifty day simple moving average of $1,006.08 and a two-hundred day simple moving average of $1,016.63. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a market cap of $1.06 trillion, a price-to-earnings ratio of 39.87, a price-to-earnings-growth ratio of 1.23 and a beta of 0.53. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,182.73.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were issued a dividend of $1.73 per share. The ex-dividend date was Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly acquired 4E Therapeutics, a developer of non-opioid pain treatments, expanding its push into the painkiller market and broadening the company beyond obesity and diabetes drugs. Article Title
• Positive Sentiment: The company announced several pipeline updates, including progress on oral and early-stage candidates and a Phase 1 Alzheimer’s program, reinforcing investor focus on Lilly’s deep R&D pipeline. Article Title
• Positive Sentiment: Market research highlighting strong growth in the global GLP-1 receptor agonist market supports the long-term demand outlook for Lilly’s obesity and diabetes franchise, which remains a key driver of the stock. Article Title
• Neutral Sentiment: Healthcare stocks were generally firmer in afternoon trading, providing a modest sector tailwind rather than a company-specific catalyst. Article Title
• Neutral Sentiment: Several articles compared Lilly with Novo Nordisk amid ongoing obesity-drug competition, but these were mostly industry commentary and not new fundamental news for LLY. Article Title
• Negative Sentiment: Investors are also weighing a “quiet new threat” to Lilly’s GLP-1 business, as employer coverage and access concerns could slow adoption or limit growth for its top-selling obesity drugs. Article Title

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Cantor Fitzgerald upped their target price on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a report on Friday, May 1st. Daiwa Securities Group upped their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Finally, Bank of America increased their price objective on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.74.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.